Senior Director, Late Oncology Program Leadership

Jazz Pharmaceuticals; City Of London; Presencial; GBP 173.000 - 259.000; Jornada completa

Ventajas ofrecidas por este puesto de trabajo

Medical, dental, vision insurance

401(k) retirement plan

Discretionary bonus

Descripción de la vacante

Jazz Pharmaceuticals is seeking a Senior Director, Head of Late Oncology Program Management to shape vision and execution for late-stage oncology and early-phase trials. You will partner with Clinical Development leadership to align study design, feasibility, and timelines with portfolio strategy.

The role requires strong governance, cross-functional collaboration across R&D and Medical Affairs, and expertise in budgeting and resource planning to optimize portfolio performance.

Formación

• Advanced degree in life sciences or related field preferred.
• Experience in clinical trial operations with senior leadership responsibility.
• Strong governance, budgeting, and strategic planning capabilities.

Responsabilidades

• Define the strategic vision and long-term direction for Late Oncology Program Management and Early Phase within GCDO.
• Lead the Clinical Operations Leadership Team and drive governance, resource planning, and operational excellence.
• Ensure end-to-end delivery of late-stage oncology trials (Phase 2b/3/4) on schedule and budget.
• Develop budgets and integrated timelines for drug project governance and executive leadership.
• Provide line management, mentorship, and development for a high-performing team.

Educación

Advanced degree (Ph.D., Pharm.D., MS, or equivalent)

Bachelor’s degree with exceptional industry experience

Descripción del empleo

Jazz Pharmaceuticals is seeking a Senior Director, Head of Late Oncology Program Management to shape vision and execution for late-stage oncology and early-phase trials. You will partner with Clinical Development leadership to align study design, feasibility, and timelines with portfolio strategy.

The role requires strong governance, cross-functional collaboration across R&D and Medical Affairs, and expertise in budgeting and resource planning to optimize portfolio performance.